RU2009125019A - Производные карбоновой кислоты - Google Patents

Производные карбоновой кислоты Download PDF

Info

Publication number
RU2009125019A
RU2009125019A RU2009125019/04A RU2009125019A RU2009125019A RU 2009125019 A RU2009125019 A RU 2009125019A RU 2009125019/04 A RU2009125019/04 A RU 2009125019/04A RU 2009125019 A RU2009125019 A RU 2009125019A RU 2009125019 A RU2009125019 A RU 2009125019A
Authority
RU
Russia
Prior art keywords
aryl
lower alkylene
lower alkyl
heterocyclic group
methyl
Prior art date
Application number
RU2009125019/04A
Other languages
English (en)
Inventor
Кендзи НЕГОРО (JP)
Кендзи НЕГОРО
Кэи ОХНУКИ (JP)
Кэи ОХНУКИ
Тосио КУРОСАКИ (JP)
Тосио Куросаки
Фумийоси ИВАСАКИ (JP)
Фумийоси Ивасаки
Ясухиро ЙОНЕТОКУ (JP)
Ясухиро ЙОНЕТОКУ
Кадзуюки ЦУТИЯ (JP)
Кадзуюки Цутия
Норио АСАИ (JP)
Норио Асаи
Сигеру ЙОСИДА (JP)
Сигеру ЙОСИДА
Такатоси СОГА (JP)
Такатоси СОГА
Дайсуке СУДЗУКИ (JP)
Дайсуке Судзуки
Original Assignee
Астеллас Фарма Инк. (Jp)
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. (Jp), Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк. (Jp)
Publication of RU2009125019A publication Critical patent/RU2009125019A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

1. Производное карбоновой кислоты, соответствующее представленной ниже формуле (I), или его фармацевтически приемлемая соль ! ! символы в формуле соответствуют следующим значениям: ! R1: -H, низший алкил, галоген-низший алкил, циклоалкил, арил, гетероциклическая группа, низший алкилен-RA, -C(O)RB, -CO2RB или -S(O)pRB, ! при условии, что низший алкилен, арил и гетероциклическая группа в R1 могут быть соответственно замещены, ! RA: циклоалкил, арил, гетероциклическая группа, -S(O)pR0, -S(O)p-арил, -S(O)p-гетероциклическая группа, -C(O)R0, -C(O)-арил, -C(O)-гетероциклическая группа, -CO2R0, -OR0, -O-арил, -O-гетероциклическая группа, -N(R0)2, -N(R0)-арил, -N(R0)-гетероциклическая группа, -CO(R0)(арил)2, -C(O)N(R0)-циклоалкил или -C(O)N(R0)-арил, ! при условии, что арил и гетероциклическая группа в RA могут быть соответственно замещены, ! RB: низший алкил, галоген-низший алкил, циклоалкил, арил, гетероциклическая группа, низший алкилен-циклоалкил, низший алкилен-арил, низший алкилен-гетероциклическая группа, низший алкилен-OR0, низший алкилен-O-арил или низший алкилен-S(O)2NH2, ! при условии, что арил и гетероциклическая группа в RB могут быть соответственно замещены, ! R0: -H или низший алкил, ! n и p: являются одинаковыми или отличаются друг от друга, и каждый равен 0, 1 или 2, ! J: -C(R6)(R7)-, -O- или -S-, ! R2, R3, R6 и R7: являются одинаковыми или отличаются друг от друга, и каждый представляет собой -H, галоген, низший алкил, -OR0 или арил, ! при условии, что R2 и R3, R3 и R6 и R6 и R7 вместе могут образовывать низший алкилен, ! R4: -H или низший алкил, ! X: одинарная связь, -CH2-, -(CH2)2-, -O-, -S-, -S(O)- или -S(O)2-, ! Y: -CH2- или -C(O)-, ! Z: C(-*), C(R8), N или N(O), при условии, что * в Z означает связь с L, ! X1 и X2: являются одинаковыми или отличаются друг от друга, и каждый п�

Claims (17)

1. Производное карбоновой кислоты, соответствующее представленной ниже формуле (I), или его фармацевтически приемлемая соль
Figure 00000001
символы в формуле соответствуют следующим значениям:
R1: -H, низший алкил, галоген-низший алкил, циклоалкил, арил, гетероциклическая группа, низший алкилен-RA, -C(O)RB, -CO2RB или -S(O)pRB,
при условии, что низший алкилен, арил и гетероциклическая группа в R1 могут быть соответственно замещены,
RA: циклоалкил, арил, гетероциклическая группа, -S(O)pR0, -S(O)p-арил, -S(O)p-гетероциклическая группа, -C(O)R0, -C(O)-арил, -C(O)-гетероциклическая группа, -CO2R0, -OR0, -O-арил, -O-гетероциклическая группа, -N(R0)2, -N(R0)-арил, -N(R0)-гетероциклическая группа, -CO(R0)(арил)2, -C(O)N(R0)-циклоалкил или -C(O)N(R0)-арил,
при условии, что арил и гетероциклическая группа в RA могут быть соответственно замещены,
RB: низший алкил, галоген-низший алкил, циклоалкил, арил, гетероциклическая группа, низший алкилен-циклоалкил, низший алкилен-арил, низший алкилен-гетероциклическая группа, низший алкилен-OR0, низший алкилен-O-арил или низший алкилен-S(O)2NH2,
при условии, что арил и гетероциклическая группа в RB могут быть соответственно замещены,
R0: -H или низший алкил,
n и p: являются одинаковыми или отличаются друг от друга, и каждый равен 0, 1 или 2,
J: -C(R6)(R7)-, -O- или -S-,
R2, R3, R6 и R7: являются одинаковыми или отличаются друг от друга, и каждый представляет собой -H, галоген, низший алкил, -OR0 или арил,
при условии, что R2 и R3, R3 и R6 и R6 и R7 вместе могут образовывать низший алкилен,
R4: -H или низший алкил,
X: одинарная связь, -CH2-, -(CH2)2-, -O-, -S-, -S(O)- или -S(O)2-,
Y: -CH2- или -C(O)-,
Z: C(-*), C(R8), N или N(O), при условии, что * в Z означает связь с L,
X1 и X2: являются одинаковыми или отличаются друг от друга, и каждый представляет собой C(R9), N или N(O),
X3 и X4: являются одинаковыми или отличаются друг от друга, и каждый представляет собой C(R10), N или N(O),
R5: низший алкил, галоген, галоген-низший алкил, -OR0 или -O-галоген-низший алкил,
R8, R9 и R10: являются одинаковыми или отличаются друг от друга, и каждый представляет собой -H, низший алкил, галоген, галоген-низший алкил, -OR0 или -O-галоген-низший алкил,
при условии, что R6 и R10 вместе могут образовывать низший алкилен, -O-низший алкилен или низший алкилен-O-,
L: -O-низший алкилен, низший алкилен-O-, -N(R11)-низший алкилен, низший алкилен-N(R11)-, -O-низший алкилен-O-, -N(R11)-низший алкилен-N(R11)-, -O-низший алкилен-N(R11)- или
-N(R11)-низший алкилен-O-, и
R11: -H, низший алкил или -C(O)R0.
2. Соединение по п.1, где J представляет собой -C(R6)(R7)-.
3. Соединение по п.2, где X и Y представляют собой -CH2-.
4. Соединение по п.3, где L представляет собой *-CH2-NH- или *-CH2-O- (где * означает связь с группой азот-содержащего бициклического кольца, с которой связан R1).
5. Соединение по п.4, где Z представляет собой CH, C(низший алкил), C(-*) (где * означает связь с L) или N.
6. Соединение по п.5, где n равно 0; или n равно 1, и R5 представляет собой галоген или низший алкил.
7. Соединение по п.6, где X1 и X2 являются одинаковыми или отличаются друг от друга, и каждый представляет собой CH или N, и X3 и X4 являются одинаковыми или отличаются друг от друга, и каждый представляет собой CH или C(галоген).
8. Соединение по п.7, где R2, R3, R6 и R7 представляет собой H.
9. Соединение по п.8, где R4 представляет собой -H.
10. Соединение по п.9, где R1 представляет собой низший алкил, галоген-низший алкил, арил, гетероциклическую группу, низший алкилен-OR0, низший алкилен-арил, низший алкилен-гетероциклическую группу или низший алкилен-O-арил (однако арил и гетероциклическая группа в R1 могут быть соответственно замещены группой, выбранной из галогена, -CN, низшего алкила, галоген-низшего алкила, -OR0 и -O-галоген-низшего алкила).
11. Соединение по п.1, которое выбрано из группы, состоящей из 3-[2-фтор-4-({[1-(2-фенилэтил)-1,2,3,4-тетрагидрохинолин-5-ил]метил}амино)фенил]пропионовой кислоты,
3-[2-фтор-4-({[1-(2-феноксиэтил)-1,2,3,4-тетрагидрохинолин-5-ил]метил}амино)фенил]пропионовой кислоты,
3-(2-фтор-4-{[(8-метил-1-пропил-1,2,3,4-тетрагидрохинолин-7-ил)метил]амино}фенил)пропионовой кислоты,
3-[2-фтор-4-({[8-метил-1-(2-фенилэтил)-1,2,3,4-тетрагидрохинолин-7-ил]метил}амино)фенил]пропионовой кислоты,
3-(2-фтор-4-{[(8-метил-1-фенил-1,2,3,4-тетрагидрохинолин-7-ил)метил]амино}фенил)пропионовой кислоты,
3-(2-фтор-4-{[(8-фенил-5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)метил]амино}фенил)пропионовой кислоты,
3-{2-фтор-4-[({1-[2-(4-метоксифенил)этил]-1,2,3,4-тетрагидрохинолин-5-ил}метил)амино]фенил}пропионовой кислоты,
3-{2-фтор-4-[({1-[2-(4-фторфенокси)этил]-1,2,3,4-тетрагидрохинолин-5-ил}метил)амино]фенил}пропионовой кислоты,
3-{4-[({1-[2-(3-хлорфенокси)этил]-1,2,3,4-тетрагидрохинолин-5-ил}метил)амино]-2-фторфенил}пропионовой кислоты,
3-[2-фтор-4-({[1-(3-фторфенил)-8-метил-1,2,3,4-тетрагидрохинолин-7-ил]метил}амино)фенил]пропионовой кислоты,
3-{2-фтор-4-({[8-метил-1-(3-метилфенил)-1,2,3,4-тетрагидрохинолин-7-ил]метил}амино)фенил}пропионовой кислоты, и
3-[4-({[1-(3,4-дифторфенил)-8-метил-1,2,3,4-тетрагидрохинолин-7-ил]метил}амино)-2-фторфенил]пропионовой кислоты,
или их фармацевтически приемлемых солей.
12. Фармацевтическая композиция, которая содержит соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
13. Фармацевтическая композиция по п.12, которая представляет собой агонист GPR40.
14. Фармацевтическая композиция по п.12, которая представляет собой усилитель секреции инсулина.
15. Фармацевтическая композиция по п.12, которая представляет собой средство для профилактики и/или лечения сахарного диабета.
16. Применение соединения по п.1 или его фармацевтически приемлемой соли для получения агониста GPR40, усилителя секреции инсулина или профилактического и/или лекарственного средства от сахарного диабета.
17. Способ профилактики и/или лечения сахарного диабета, который включает введение пациенту эффективного количества соединения по п.1 или его соли.
RU2009125019/04A 2006-12-01 2007-11-29 Производные карбоновой кислоты RU2009125019A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006325388 2006-12-01
JP2006-325388 2006-12-01

Publications (1)

Publication Number Publication Date
RU2009125019A true RU2009125019A (ru) 2011-01-10

Family

ID=39467887

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009125019/04A RU2009125019A (ru) 2006-12-01 2007-11-29 Производные карбоновой кислоты

Country Status (15)

Country Link
US (1) US20100152165A1 (ru)
EP (1) EP2096109A1 (ru)
JP (1) JPWO2008066097A1 (ru)
KR (1) KR20090083935A (ru)
CN (1) CN101553469A (ru)
AR (1) AR064049A1 (ru)
AU (1) AU2007326449A1 (ru)
CA (1) CA2671080A1 (ru)
IL (1) IL198970A0 (ru)
MX (1) MX2009005797A (ru)
NO (1) NO20092471L (ru)
RU (1) RU2009125019A (ru)
TW (1) TW200838526A (ru)
WO (1) WO2008066097A1 (ru)
ZA (1) ZA200903646B (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN102421739A (zh) * 2009-04-22 2012-04-18 安斯泰来制药株式会社 羧酸化合物
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2820005A1 (en) * 2012-02-28 2015-01-07 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
EP3092240B1 (en) * 2014-01-10 2018-12-05 Eli Lilly and Company Isopropyl triazolo pyridine compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2015176267A1 (en) * 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
DK3325490T3 (da) * 2015-07-23 2020-02-03 Takeda Pharmaceuticals Co 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister
US10703712B2 (en) 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US20190062277A1 (en) * 2015-09-16 2019-02-28 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2017049172A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
CN110088089B (zh) * 2016-10-25 2023-08-29 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110312714B (zh) * 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3573959B1 (en) * 2017-01-26 2021-07-28 Boehringer Ingelheim International GmbH Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3573952B1 (en) * 2017-01-26 2021-07-14 Boehringer Ingelheim International GmbH Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. BICYCLIC ANTIDIABETIC COMPOUNDS
CN110092774B (zh) * 2018-01-29 2022-04-08 中国科学院上海药物研究所 芳香丙酸类衍生物、及其制备方法和用途
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005019151A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Ppar modulators
US20070093476A1 (en) 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
CN1946666A (zh) 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体

Also Published As

Publication number Publication date
US20100152165A1 (en) 2010-06-17
NO20092471L (no) 2009-08-25
EP2096109A1 (en) 2009-09-02
TW200838526A (en) 2008-10-01
KR20090083935A (ko) 2009-08-04
CA2671080A1 (en) 2008-06-05
WO2008066097A1 (en) 2008-06-05
IL198970A0 (en) 2010-02-17
JPWO2008066097A1 (ja) 2010-03-11
ZA200903646B (en) 2010-08-25
AU2007326449A1 (en) 2008-06-05
AR064049A1 (es) 2009-03-11
MX2009005797A (es) 2009-06-08
CN101553469A (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
RU2009125019A (ru) Производные карбоновой кислоты
RU2338745C1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
JP2008513499A5 (ru)
JP2011527334A5 (ru)
RU2439068C2 (ru) Модуляторы mglur5
RU2011105151A (ru) Азольные соединения
RU2008137612A (ru) Амидное производное или его соли
JP2011519865A5 (ru)
RU2009114747A (ru) Производные пиррола, применимые в лечении цитокин-опосредованных заболеваний
JP2008513498A5 (ru)
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2016512825A5 (ru)
RU2015121948A (ru) Агонист рецептора gpr40, способы его получения и фармацевтические композиции, содержащие его в качестве активного ингредиента
CA2598294A1 (en) Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2006513202A5 (ru)
RU2008146088A (ru) Оксадиазолидиндионовое соединение
JP2011502958A5 (ru)
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP2008513514A5 (ru)
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
JP2008513515A5 (ru)
RU99105567A (ru) Производные пропионовой кислоты и их использование

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110311